Brokerages expect Express Scripts (NASDAQ:ESRX) to report sales of $24.76 billion for the current quarter, according to Zacks Investment Research. Eleven analysts have made estimates for Express Scripts’ earnings. The lowest sales estimate is $24.28 billion and the highest is $25.50 billion. Express Scripts posted sales of $24.65 billion during the same quarter last year, which would indicate a positive year over year growth rate of 0.4%. The business is scheduled to issue its next earnings report after the market closes on Wednesday, May 2nd.
According to Zacks, analysts expect that Express Scripts will report full-year sales of $100.87 billion for the current financial year, with estimates ranging from $99.93 billion to $102.06 billion. For the next year, analysts anticipate that the firm will report sales of $103.31 billion per share, with estimates ranging from $99.59 billion to $107.17 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Express Scripts.
Express Scripts (NASDAQ:ESRX) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $2.16 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.09 by $0.07. Express Scripts had a return on equity of 25.19% and a net margin of 4.51%. The firm had revenue of $25.38 billion during the quarter, compared to analyst estimates of $25.07 billion. During the same period last year, the company posted $1.88 EPS. The business’s quarterly revenue was up 2.1% on a year-over-year basis.
In other Express Scripts news, VP Everett Neville sold 4,895 shares of Express Scripts stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $75.26, for a total transaction of $368,397.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christine Houston sold 19,889 shares of Express Scripts stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $76.69, for a total value of $1,525,287.41. The disclosure for this sale can be found here. 0.79% of the stock is currently owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. James Investment Research Inc. boosted its stake in Express Scripts by 2.2% during the 4th quarter. James Investment Research Inc. now owns 30,241 shares of the company’s stock valued at $2,257,000 after purchasing an additional 656 shares during the last quarter. First National Bank of Omaha boosted its stake in shares of Express Scripts by 7.4% in the 4th quarter. First National Bank of Omaha now owns 11,060 shares of the company’s stock worth $825,000 after buying an additional 765 shares during the last quarter. Palladium Partners LLC boosted its stake in shares of Express Scripts by 4.1% in the 4th quarter. Palladium Partners LLC now owns 19,666 shares of the company’s stock worth $1,468,000 after buying an additional 772 shares during the last quarter. Alpha Windward LLC boosted its stake in shares of Express Scripts by 35.9% in the 4th quarter. Alpha Windward LLC now owns 2,981 shares of the company’s stock worth $223,000 after buying an additional 787 shares during the last quarter. Finally, Hendershot Investments Inc. grew its position in Express Scripts by 1.0% in the fourth quarter. Hendershot Investments Inc. now owns 81,895 shares of the company’s stock worth $6,113,000 after acquiring an additional 840 shares in the last quarter. Institutional investors and hedge funds own 89.31% of the company’s stock.
Shares of ESRX stock traded down $0.94 during mid-day trading on Monday, hitting $73.80. The company’s stock had a trading volume of 1,885,728 shares, compared to its average volume of 5,091,660. Express Scripts has a 52 week low of $55.80 and a 52 week high of $85.07. The company has a current ratio of 0.67, a quick ratio of 0.55 and a debt-to-equity ratio of 0.83. The firm has a market cap of $40,711.00, a PE ratio of 10.39, a price-to-earnings-growth ratio of 0.89 and a beta of 0.99.
TRADEMARK VIOLATION WARNING: This news story was first posted by Week Herald and is the property of of Week Herald. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://weekherald.com/2018/04/26/24-76-billion-in-sales-expected-for-express-scripts-esrx-this-quarter.html.
Express Scripts Company Profile
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.